

Press Release
New Delhi
August 19, 2009

EasyFive* Injects Cheer for Panacea Biotec; USD 222.37 million Award for Panacea Biotec by UNICEF

India's 2nd largest biotechnology company and WHO pre-qualified vaccine major Panacea Biotec has received an Award Notification for supply of its **EasyFive** (pentavalent vaccine), from UNICEF for years 2010, 2011 and 2012. The total value of the award is USD 222.37 million (over Rs.1067 crores). **EasyFive** is **world's first fully liquid** pentavalent vaccine introduced in India by Panacea Biotec in January 2005, which immunizes children against five dreadful diseases (Diphtheria+ Tetanus+ whole cell Pertussis+ Hepatitis B+ Hemophilus Influenza Type b) of early childhood.

Panacea Biotec received the pre-qualification for **EasyFive** by WHO in July last year. Pentavalent vaccines are used by UN agencies (UNICEF, PAHO etc.) to vaccinate & save precious lives of millions of children in the developing world. **EasyFive** offers a befitting solution to overcome complexity of childhood vaccination program.

Highlighting this significant achievement, Dr. Rajesh Jain, Joint Managing Director said, "We have always believed that Innovation delivers sustainable business value and we are glad to witness the same once again. This award is one of the growth drivers which would have a significant impact on our overall performance in the coming years. I would like to congratulate all our team members, employees, shareholders and other stakeholders on this occasion. We look ahead with confidence and conviction about our performance year after year."



As available in India

Panacea Biotec has been focusing its R&D efforts on immunization segment. It has launched world's first fully liquid vaccine with brands such as, 'EasyFour' & '**EasyFive**'. As part of its overall strategy to garner a firm foothold in various immunization programs across the globe, Panacea Biotec has partnered with WHO & UNICEF in their effort to maximize coverage of vaccines under the Expanded Program on Immunization (EPI). The company has also been granted pre-qualification by WHO for its other two combination vaccines, EasyFour (DTP + Hib) and Ecovac (DTP + Hep B). Panacea Biotec is also a pre-qualified supplier of Oral Polio Vaccine (OPV) and Hepatitis-B vaccines to UN agencies.

Pentavalent vaccines for children are preferred by health authorities and individuals world over due to protection against five dreadful diseases in one shot as well as ease of administration. The combined demand of all combination pediatric vaccines worldwide was valued at USD 600 million in 2005 and is estimated to grow up to USD 1.6 billion by 2012. Developing countries would need a combination vaccine to the tune of around 300 million doses annually.

About Panacea Biotec

Panacea Biotec is one of India's leading research-based health management companies with established research, manufacturing and marketing capabilities. Panacea Biotec is the 2nd largest vaccine producer in India. Panacea Biotec has been ranked as the 3rd largest biotechnology company (ABLE Survey 2009) and is also amongst the top 50 pharmaceutical companies in India. The product portfolio of the Company includes highly innovative vaccines, biopharmaceuticals and prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products. The company has collaborations and tie-ups with leading national and international research organizations and corporations. The company's state of the art manufacturing facilities for vaccines and pharmaceutical formulations comply with the US-FDA, UK-MHRA, SA-MCC and WHO-cGMP standards. The company has five research and development centers. It has around 2800 employees including over 280 highly skilled scientists. The company also has 24 product patents, valid in more than 60 countries worldwide.

*** Easyfive (Pentavalent) vaccine is available in different markets with antigens used from different sources i.e. Easyfive in India uses Hib from Novartis Vaccines and is meant for use in Indian market only whereas Easyfive PQ by WHO uses Hib developed by Panacea Biotec.**

Panacea Biotec Ltd.

B-1 Extn./G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India
Ph.: 91-11-4167 9000, 4167 8000, Fax: 91-11-26940621, 26940199, 41679070, Email: corporate@panaceabiotec.com

For further details please contact:

Mr. Pradeep Kumar Jain
GM - Corporate Communications & Govt. Affairs
Mobile: 09313482886
Land Line: 011-41678000; Fax: 011-41679096
Email: pradeepjain@panaceabiotec.com
Website: www.panaceabiotec.com

Disclaimer

Except for the historical information contained herein, statements in this Release which contain words or phrases such as 'will', 'would', 'indicating', 'expected to' etc., and similar expressions or variations of such expressions may constitute 'forward-looking statements'. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, future business plans, our growth and expansion in business, the impact of any acquisitions, our financial capabilities, technological implementation and changes, the actual growth in demand for our products and services, cash flow projections, our exposure to market risks as well as other general risks applicable to the business or industry. Panacea Biotec undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date thereof.